JPRN-UMIN000005301已完成2 期
Phase II Study of Combination Epitope Peptides with gemcitabine for Advanced/metastatic Pancreatic Cancer - Phase II Study of Combination Epitope Peptides with gemcitabine for Advanced/metastatic Pancreatic Cancer
YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE Department of Digestive Surgery and Surgical Oncology0 个研究点目标入组 40 人开始时间: 2011年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Severe heart diseases 2. Wish for pregnancy 3. Active infection 4. Steroid or immunosuppressive therapy 5. Allergy for using epitope peptides 6. Mental and nervous disorder 7. Massive pleural or abdominal effusions 8. Rapid growth of liver metastasis 9. Doctors opinion
研究者
相似试验
已完成
2 期
Phase II Study of Combination Epitope Peptides for Advanced/metastatic Pancreatic CancerAdvanced/metastatic Pancreatic CancerJPRN-UMIN000007505YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE Department of Digestive Surgery and Surgical Oncology50
招募中
2 期
Multicenter Phase II Study of Epitope Peptides with UFT/LV following curative resection for stage III Colorectal cancerJPRN-UMIN000003552Kinki University School of Medicine Department of Surgery110
已完成
1 期
Phase I clinical trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinomaadvanced renal cell carcinomaJPRN-UMIN000004911Department of Urology, Kinki University School of Medicine18
已完成
1 期
Phase I clinical trial of epitope peptides based vaccines both targeting RNF43 and VEGFR2 in patients with advanced colorectal cancer.unresectable colorectal cancerJPRN-UMIN000000956Institute of Medical Science The University of Tokyo6
进行中（未招募）
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6